Antihypertensive effect of an enzymatic hydrolysate from Styela clava flesh tissue in type 2 diabetic patients with hypertension.
10.4162/nrp.2017.11.5.396
- Author:
Seok Chun KO
1
;
Won Kyo JUNG
;
Seung Hong LEE
;
Dae Ho LEE
;
You Jin JEON
Author Information
1. Marine-Integrated Bionics Research Center, Pukyong National University, Busan 48513, Korea.
- Publication Type:Clinical Trial ; Original Article
- Keywords:
Aquatic organisms;
protein hydrolysates;
clinical trial;
antihypertensive agents
- MeSH:
Antihypertensive Agents;
Apolipoproteins;
Aquatic Organisms;
Blood Pressure;
Capsules;
Diabetes Mellitus, Type 2;
Double-Blind Method;
Eating;
Homeostasis;
Humans;
Hypertension*;
Insulin;
Insulin Resistance;
Plasma;
Protein Hydrolysates;
Triglycerides
- From:Nutrition Research and Practice
2017;11(5):396-401
- CountryRepublic of Korea
- Language:English
-
Abstract:
BACKGROUND/OBJECTIVES: In this randomized, placebo-controlled, double-blind study, we evaluated the antihypertensive effects of enzymatic hydrolysate from Styela clava flesh tissue in patients with type 2 diabetes mellitus (T2DM) and hypertension. SUBJECTS/METHODS: S. clava flesh tissue hydrolysate (SFTH) (n = 34) and placebo (n = 22) were randomly allocated to the study subjects. Each subject ingested two test capsules (500 mg) containing powdered SFTH (SFTH group) or placebo capsules (placebo group) during four weeks. RESULTS: In the SFTH group, systolic and diastolic blood pressure decreased significantly 4 weeks after ingestion by 9.9 mmHg (P < 0.01) and 7.8 mmHg (P < 0.01), respectively. In addition, the SFTH group exhibited a significant decrease in hemoglobin A1c with a tendency toward improvement in homeostasis model assessment of insulin resistance, triglyceride, apolipoprotein B and plasma insulin levels after 4 weeks. No adverse effects were observed in other indexes, including biochemical and hematological parameters in both groups. CONCLUSION: The results of our study suggested that SFTH exerts a regulatory, antihypertensive effect in patients with T2DM and hypertension.
